Navigation Links
Albireo Announces Positive Results in Patients With Chronic Idiopathic Constipation From a Phase IIb trial of A3309
Date:10/12/2010

rent dose levels (5, 10 and 15 mg orally once a day) of the investigational drug A3309 during an eight week trial. Analyses of the data show clinically meaningful and statistically significant improvement for patients treated with A3309 compared to placebo-treated patients. A3309 is a first-in-class IBAT inhibitor with minimal systemic exposure which is developed for the treatment of CIC and constipation-predominant irritable bowel syndrome (IBS-C).

The primary efficacy endpoint, change from baseline in spontaneous bowel movements (SBMs), showed a dose-dependent increase and highly significant results were obtained for the two highest dose levels. In addition, the secondary endpoints of effects on SBM and complete SBM (CSBM) frequencies were also dose dependent and statistically significant. Bloating and straining, important constipation symptoms, also decreased significantly during A3309 treatment. The effect of A3309 was rapid and a significantly higher proportion of the A3309-treated patients had a CSBM within 24 hours of the first administration. The beneficial effects were maintained over the eight week trial period.

"A3309 has a unique and novel mode of action which utilizes the body's physiologic processes to induce an increase in bowel movements. The results of this Phase IIb study show that A3309 has the potential to be an important therapeutic addition for patients with chronic constipation. I am sure that scientists and clinicians alike look forward to seeing further results with this exciting new compound" said William D. Chey, MD, Professor of Internal Medicine, University of Michigan, Ann Arbor.

"More than 30 million individuals suffer from CIC and IBS-C and the results of this Phase IIb trial further support the potential of A3309 to be an important treatment for these patients. The data in the trial presented today provide a solid base for moving forward into Phase III in 2011" said Hans Graffner, Chief Medical Officer of Albi
'/>"/>

SOURCE Albireo AB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation
2. Gen-Probe Announces Webcast of Third Quarter 2010 Earnings Conference Call
3. Halozyme Therapeutics Announces Implementation of Development Focused Strategy
4. Pioneer® Surgical Technology, Inc. Announces Plans to Establish Manufacturing and Distribution Facility in Ireland
5. Webcast Alert: CEL-SCI Corp. (CVM) Announces the Biotech, Healthcare and Pharma Virtual Conference
6. IRIDEX Announces Commercial Availability of New Adjustable & Intuitive EndoProbe® Device for Eye Surgery
7. TriReme Medical Announces $17 Million Series D Financing
8. Warner Chilcott Announces FDA Approval of Next Generation Actonel
9. Arable Corporation Announces New Technology for Clinical Trial Industry
10. PharmaNet Development Group Announces Observational Research Survey
11. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD ) ... China based on the number of directly operated ... Meeting of Shareholders (the "AGM") on October 22, 2014 at 10:00 ... room of the Company at 6th Floor, Tower B, Xinnengyuan Building, ... Guangdong Province 518054, People,s Republic of China ...
(Date:9/19/2014)... 2014  Today DePuy Synthes Companies of Johnson ... systems featuring its proprietary variable angle locking technology. ... to match patient anatomy and fracture pattern and ... systems are being introduced in conjunction with the ... the International Federation of Foot & Ankle Societies ...
(Date:9/19/2014)... 19, 2014 /PRNewswire-iReach/ -- "United States ... provides key market data on the ... The report provides value, in millions ... units) within market categories – Bronchoscopes, ... & Gastroscopes, Duodenoscopes, Laparoscopes, Hysteroscopes, Sinuscopes, ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Schedules Annual General Meeting of Shareholders for October 22, 2014 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5
... The recent ruling by federal judge Royce C. Lamberth halting ... disease research but not necessarily for arthritis.  A key note ... Treatment of Osteoarthritis of the Knee " will be made ... American College of Rheumatology in Atlanta. Osteoarthritis (OA) ...
... CHARLOTTE, N.C., Aug, 24 BlueDot Medical, Inc. ... BlueDot was ranked #2,572 on the annual list ... and #213 among healthcare businesses. (Logo: ... ) "We are extremely proud to ...
Cached Medicine Technology:Embryonic Stem Cell Research in the Toilet, According to Arthritis Treatment Center 2
(Date:9/21/2014)... of cancer patients who smoke, those using e-cigarettes (in ... equally or less likely to have quit smoking traditional ... , a peer-reviewed journal of the American Cancer Society, ... e-cigarettes for helping cancer patients give up smoking. , ... patients who smoke should be advised to quit. But ...
(Date:9/21/2014)... Texas (PRWEB) September 22, 2014 ... originally launched in 1997, and is used prophylactically ... and adults. Its active ingredient, budesonide, is an ... corticosteroid receptor. AstraZeneca’s Pulmicort franchise includes the Pulmicort ... than six years of age, Pulmicort Respules for ...
(Date:9/21/2014)... More than a quarter of house fires are started ... two ways. The first type of dryer fire occurs when ... of dryer fire occurs when lint builds up in the dryer ... to malfunctioning electrical systems so if it doesn’t appear to be ... are some ways that you can prevent dryer fires. , Clean ...
(Date:9/21/2014)... 21, 2014 Burnaby Physiotherapists at Absolute ... clients in order to help them with preventative care. ... the clinic that will help clients understand their problem ... take active participation in the healing process. With higher ... will be able to facilitate the therapy that is ...
(Date:9/21/2014)... 21, 2014 Waldorf Risk Solutions, ... Portal designed for Diocesan risks. The portal features ... support effective risk management and loss control client ... coinciding with Waldorf’s exhibition at the Diocesan Fiscal ... applications were developed in collaboration with three Risk ...
Breaking Medicine News(10 mins):Health News:E-cigarettes unhelpful in smoking cessation among cancer patients 2Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Restoration Local Offers Tips to Avoid Dryer Fires 2Health News:Restoration Local Offers Tips to Avoid Dryer Fires 3Health News:Burnaby Physiotherapists Now Provide Educational Information for Preventative Care 2Health News:Waldorf Risk Solutions Releases New Risk Management Portal 2
... , , CHICAGO, July 14 ... people of Chicago, SAVE THE PATIENT, a not-for-profit patient-focused organization, ... Chicago Access Network Television (CAN-TV) airing Monday, July 20, 2009 ... , Monday,s program will feature a ...
... , , , ... leading developer of video analytics-enabled products, announced today that ... Cernium,s server-based enterprise video analytics software solution. Perceptrak will ... the Baltimore, Maryland medical center campus. , ...
... , , OAKLAND, Calif., July 14 ... Health Manager, Kaiser Permanente,s personal health record, are overwhelmingly satisfied with ... from the recent Kaiser Permanente survey examining Web site usage and ... Congress, 5th Annual Leadership Summit on Medicare in Washington, D.C. , ...
... prevent injuries, experts say , TUESDAY, July 14 (HealthDay News) ... and your mental health. , But running can be tough ... shin splints, stress fractures, pulled muscles, ankle sprains, plantar fasciitis ... back. , To prevent injuries, make sure you take precautions, ...
... better screening: study , TUESDAY, July 14 (HealthDay News) ... cancers noted in the United States since 1980, and scientists ... A new study finds that thyroid tumors of all sizes ... more aggressive screening would be expected to detect. , ...
... , , SAN DIEGO, ... today announced that OraVerse(R), the company,s premier dental pharmaceutical product, has ... of its Top 100 Products for 2009. The full results ... , , OraVerse is the first ...
Cached Medicine News:Health News:Women's Health - An Intimate Discussion 2Health News:Johns Hopkins Medical Institutions Deploys Perceptrak(R) by Cernium 2Health News:Kaiser Permanente Survey Shows Seniors Embrace Internet to Manage Their Health 2Health News:Kaiser Permanente Survey Shows Seniors Embrace Internet to Manage Their Health 3Health News:Get the Most Out of Your Run 2Health News:Get the Most Out of Your Run 3Health News:Increase in Thyroid Cancer Puzzles Experts 2Health News:OraVerse (R) Selected by Dentistry Today Magazine as One of the Top 100 Products of 2009 2Health News:OraVerse (R) Selected by Dentistry Today Magazine as One of the Top 100 Products of 2009 3
Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl...
... that quantitatively measure two important cardiac risk ... serum or plasma homocysteine level is increasingly ... factor for cardiovascular disease. And numerous studies ... levels of Lp(a) with increased risk of ...
... ELISA products for autoimmune testing feature single-well ... well as specific reflex tests including dsDNA, ... SS-A (Ro), SS-B (La), Scl-70 and Jo-1. ... a full line of products for Cardiolipins ...
Anti-Skin Antibody (ASA) Test Kit: Pemphigus and Bullous Pemphigoid...
Medicine Products: